Ceritinib Aggravates Glycemic Control in Insulin-treated Patients with Diabetes and Metastatic ALK-positive Lung Cancer

We herein report a 75-year-old woman with insulin-treated diabetes and metastatic anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer who received ceritinib, a second-generation ALK inhibitor, and achieved dramatic tumor reduction. However, her fasting blood glucose increased, par...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakuma, Ikki, Nagano, Hidekazu, Yoshino, Ichiro, Yokote, Koutaro, Tanaka, Tomoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465015/
https://www.ncbi.nlm.nih.gov/pubmed/30449809
http://dx.doi.org/10.2169/internalmedicine.1870-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465015/
https://www.ncbi.nlm.nih.gov/pubmed/30449809
http://dx.doi.org/10.2169/internalmedicine.1870-18

Ejemplares similares